🔎 Trials Near Me

Home › Depression › NCT02568878

Creatine for Depressed Male and Female Methamphetamine Users

RecruitingPhase 3

An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users

Who can join

Ages 18 to 59 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
* Current diagnosis of major depressive disorder (primary or substance-induced)
* Current diagnosis of an anxiety disorder (primary or substance-induced)
* Current Hamilton Depression Rating scale score \> or = to 16
* Current Hamilton Anxiety Scale score \> = to 18
* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation

Exclusion Criteria:

* Persons unable to provide adequate informed consent
* Persons who are at clinically significant suicidal or homicidal risk
* Primary substance-related diagnosis other than methamphetamine dependence or abuse
* Positive pregnancy test (females only)
* History of renal disease
* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing
* History of hypersensitivity reaction to creatine

About the study

* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

What is being tested

Sponsor: Montana State University · Participants: 29 · Started: 2015-11

Contact the study team

Official record on ClinicalTrials.gov — NCT02568878

Locations in the U.S.

MontanaMontana State University College of Nursing (Missoula campus), Missoula

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.